Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This research study is being done to learn what effect 12 months of treatment with oral
hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).
The hypothesis is that treatment with HCQ is safe and tolerable in patients with autosomal
dominant retinitis pigmentosa (adRP) caused by P23H-RHO, and may arrest progression of
retinal degeneration by altering the autophagy pathway in photoreceptors.
Participants that meet eligibility and agree to the study will be asked to take the study
medication (HCQ) for 12 months and have evaluations for up to approximately 18 months from
the baseline visit. There will be a total of 6 visits (1 is a phone visit) and will include
general examinations, blood work, electrocardiograms, along with special testing of the
retina.